Physician profile
George C Wu
NPI 1144227158
$2,478.22
in general payments reported to CMS, 2019-2025
28 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $179 · 2021: $70.19 · 2022: $113 · 2023: $276 · 2024: $370 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $453.26 | 2019-2025 | |
| Amgen INC. | $428.15 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $249.59 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $228.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.50 | 2023-2025 | Jardiance |
| Akcea Therapeutics, INC. | $122.20 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $94.15 | 2019-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $93.31 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $72.89 | 2019-2020 | |
| Abbott Laboratories | $59.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $58.20 | 2023-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $49.93 | 2019 | |
| Heartflow, INC. | $44.80 | 2022-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $42.55 | 2023 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.85 | 2021-2023 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $24.96 | 2019 | |
| Merck Sharp & Dohme LLC | $24.22 | 2025 | Verquvo |
| Boston Scientific Corporation | $22.34 | 2024 | Bodyguardian |
| Kestra Medical Technology Services, INC. | $21.47 | 2025 | Assure Wcd |
| Recor Medical INC | $20.76 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $19.34 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.64 | 2023 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $16.09 | 2024 | |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $15.34 | 2020 | |
| Medtronic Vascular, INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.